View this on-demand Webcast, read expert-authored ClinicalThought commentaries, or download the slides to review key data and representative patient cases that highlight new and emerging immunotherapy treatments for ALL.
The FDA approvals of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel have expanded our treatment options for relapsed/refractory ALL. Read my take on where these immunotherapies most benefit our patients and what they may offer us in future clinical practice.
Data to be presented at the 2018 American Society of Hematology conference are poised to change how we manage ALL.
Do you have questions about the optimal use of immunotherapy for your patients with Ph-negative ALL? In this commentary, Renier J. Brentjens, MD, PhD; Aaron C. Logan, MD, PhD; Matthew Wieduwilt, MD, PhD; and I answer key questions from the audience at a recent ASH symposium. Review how BiTE antibodies, antibody–drug conjugates, and CAR T-cell therapy fit into the treatment landscape.
In this on-demand Webcast from the live satellite symposium at the ASH 2018, expert faculty review key data and management strategies with the use of BiTE antibodies, antibody-drug conjugates, and CAR T-cell therapy in adult patients with Ph-Negative ALL.
Download this slideset from a live ASH symposium reviewing the contemporary management of ALL, risk features in and treatment of adults, strategies for incorporating immunotherapy in the frontline setting, and the importance of quantifying MRD.
Download this slideset from a live ASH symposium focused on the efficacy and safety of inotuzumab ozogamicin, with or without dose-reduced hyperCVD, as a salvage regimen and in the frontline setting for patients with ALL.
Download this slideset from a live ASH symposium to learn how blinatumomab is currently used for the treatment of relapsed/refractory ALL and how its role could change in the future.
Download this slideset from a live ASH symposium to explore how CAR T-cell therapy may be optimally integrated into the care of patients with relapsed/refractory ALL.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.